Sign Up For Future Updates
Pancreatic Seromic™ Profiling AssaySerum antibodies of pancreatic cancer markersPancreatic cancer is the fifth leading cause of cancer-related death in adults. According to the American Cancer Society, and estimated 43,920 people will be newly diagnosed in 2012. Very little is know about how to prevent this disease and it occurs without early signs or symptoms. Most significantly pancreatic cancer usually remains undetected until it has spread beyond the pancreas (1), an event that adversely affects prognosis. New therapies and earlier diagnosis will play a critical role in the advancement of treatment of pancreatic cancer. Biomarkers recently identified through proteomic and genomic technologies could be useful as biomarkers for the early diagnosis, therapeutic targets and disease response markers (2,3). A diagnostic test for screening high-risk groups such as diabetics and patients with chronic pancreatitis would be of very great value in reducing the impact of this disease on those groups. SEREX studies identify important pancreatic antigens The SEREX technique has been successfully applied to the discovery and identification of tumor antigens in many types of cancer (www.cancerimmunity.org/SEREX/introduction.htm). SEREX was applied to the discovery of pancreatic cancer antigens by Nakatsura et al. (4). From this study eighteen genes were isolated. One of them, coactosin-like protein (CLP), was subsequently shown by the same group to be a target for cell-mediated immunity in pancreatic patients (5). Many of the SEREX antigens in pancreatic cancer have been included in the Prostate Seromic Assay. Antigens in the Pancreatic Seromic Assay The Pancreatic Seromic Assay has been developed to enable the study of humoral immune responses to pancreatic antigens to help the development of diagnostics and drugs for pancreatic cancer. The antigens included in the assay were derived as a combination of early SEREX discoveries and the more recent research undertaken by Serametrix in collaboration with leading academics. The screening of patient serum to study immune responses is now available as a service to academics, clinicians and pharmaceutical companies.
For more information on the most current list of antigens, email us today.
References: 1. A Mouse to Human Search for Plasma Proteome Changes Associated with Pancreatic Tumor Development. Vitor M Faca, et al. June 2008 Issue of PLoS Medicine. 2. Patwa, TH et al, The identification of phosphoglycerate kinase-1 and histone H4 autoantibodies in pancreatic cancer patient serum using a natural protein microarray., Electrophoresis. 2009 Jun;30(12):2215-26. 3. Proteomic Profiling of Pancreatic Cancer for Biomarker Discovery. Ru Chen , Sheng Pan, Teresa A. Brentnall, and Ruedi Aebersold, Molecular & Cellular Proteomics 4:523-533, 2005. 4. Nakatsura, T. et al, Gene cloning of immunogenic antigens overexpressed in pancreatic cancer., Biochem Biophys Res Commun. 2001 Mar 9;281(4):936-44 5. Nakatsura, T. el al, Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method, Eur J Immunol. 2002 Mar;32(3):826-36 |
|